Retatrutide 10mg
99.682% HPLC PurityA triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial.

SKU: PEP-045-10MG
An investigational amylin receptor agonist, supplied as a 10mg lyophilised vial. Research use only. Preorder — ships with the first batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Preorder: dispatched once the next batch arrives, tracked with Australia Post
A triple GLP-1, GIP and glucagon receptor agonist, supplied as a 10mg lyophilised vial.
The same triple receptor agonist as our 10mg vial, supplied at double the strength.
The same triple receptor agonist as our 10mg vial, supplied at triple the strength.
An investigational amylin receptor agonist, supplied as a 10mg lyophilised vial.
It is a newer compound and the published literature is limited; research interest centres on amylin receptor pharmacology.
This product is currently available to preorder and ships once the first batch has been produced and tested. Strictly for in-vitro laboratory research only.
An investigational amylin receptor agonist, supplied as a 10mg lyophilised vial. It is a newer compound and the published literature is limited; research interest centres on amylin receptor pharmacology. All use is strictly for in-vitro laboratory research only.
This product is a preorder. It is not held in stock yet and ships with the first batch; you will be emailed when your order is dispatched.
Batch testing documentation is published for each batch once it has been produced and tested. Contact us before ordering if you need it first.
Store lyophilised product at −20°C, protected from light and moisture, and avoid repeated freeze-thaw cycles.
No. Eloralintide is supplied for in-vitro laboratory research only and is not approved for human consumption or therapeutic use. Scheduling attaches to the substance and changes over time; verify the current status against the TGA Poisons Standard.
Eloralintide 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to Eloralintide. Provided for research context — not medical advice.
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Briere DA, Qu H, Lansu K, et al. · Molecular metabolism · 2025
PMID: 41109426
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, et al. · Lancet (London, England) · 2025
PMID: 41207310
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Bhattachar S, Tham LS, Tidemann-Miller B, et al. · Diabetes, obesity & metabolism · 2026
PMID: 41559929
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey CJ, Flatt PR, Conlon JM · Peptides · 2026
PMID: 41747885
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.